I'm still not putting too much on it. I find it in

I'm still not putting too much on it. I find it intriguing, but they did just publish 3 PRs today with minimal info on the cancer one. So maybe with the proxy fight, cancer trials, HIV bla, CRO suit, new Alzheimer's/stroke trials and other info they figured on getting a lot of more in depth questions. Which I have found these emerging growth casts to be pretty decent. I do miss the bumbling wall Street reporter of yesteryear. The lady that moderates these so far has been very good, and the questions have been solid so far vs some of the "where's my dividend" gems on prior conference calls